Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Alaa Sada
Study ID
NCT07573163
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Adrenalectomy; Status
  • Mild Autonomous Cortisol Secretion (MACS)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Tirzepatide will be initiated at the lowest dose of 2.5 mg once weekly for 4 weeks. The dose will then be titrated every 4 weeks based on patient tolerance to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
  • Standard medical treatment — OTHER
    Participants will receive postoperative care and follow up per institutional standard-of-care practices

Study Details

Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain. Surgical removal of the adrenal gland (adrenalectomy) is standard treatment, but some patients continue to have metabolic health problems after surgery. This randomized study will evaluate whether treatment with tirzepatide after adrenalectomy improves metabolic outcomes in patients with MACS compared with adrenalectomy alone.

Key Dates

Start date
Jul 31, 2026
Status verified
Jan 2026
Primary completion
Jul 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
34 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: GLP-1 Treatment
    GLP-1 dose of 2.5 mg once weekly for 4 weeks. The dose will then be titrated every 4 weeks based on patient tolerance to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
  • Active Comparator: Standard of Care arm
    Participants in this arm will receive standard of care management for as determined by their treating clinician.

Primary Outcome Measure

Change in systolic blood pressure [ Time Frame: Baseline and 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Pittsburgh Medical CenterPittsburghPennsylvania15213-

Find similar trials in Pittsburgh, PA

By research site
University of Pittsburgh Medical Center· Pittsburgh, PA

Related Studies